IDIX to report Phase II trial of IDX184, designed for the treatment of hepatitis C virus (HCV) infection.
(Some of you may already see this)
In February – March 2010, we expect Idenix Pharmaceuticals, Inc. (IDIX), to release the data from the Phase II trial of IDX184, designed for the treatment of hepatitis C virus (HCV) infection. The ongoing, Phase II trial is comparing the efficacy and safety of oral IDX184 in combination with pegylated-interferon alpha/peg-IFN alpha and ribavirin/RBV (the current standard of care for HCV infection) to placebo plus peg-IFN alpha and RBV in approximately 80 treatment-naïve HCV genotype 1 patients, who did not receive any prior therapy. The trial is divided into four dosage groups (50mg, 100mg, 150mg and 200mg once-daily), with each group comprising of 20 patients, of which 16 are receiving IDX184 in combination with peg- IFN alpha and RBV and 4 are being treated with placebo plus peg-IFN alpha and RBV for 14 days. The data from this Phase II combination trial will be released sometime in February - March 2010.
Hepatitis C infection is caused by a virus called HCV. There are various types of HCV that cause hepatitis C infection. These different types of HCVs are classified under six groups, called genotypes, denoted by genotype 1 to 6. Of these, genotype 1 is the most common type of HCV, which accounts for nearly 70% of all HCV infections and is regarded as the most difficult HCV to treat.
Market Data 
Markets 
AI
